
Oncologist

No OPD information available
Colorectal Cancer
Pancreatic Cancer
Esophageal Cancer
Familial Adenomatous Polyposis
Hypophosphatemia
Liver Cancer
Lung Cancer
Lynch Syndrome
Magnesium Deficiency
Neuroendocrine Tumor
Neurogenic Bladder
Ovarian Cancer
Pancreatic Ductal Adenocarcinoma
Small Cell Lung Cancer (SCLC)
Lara R. Lipton is a female medical professional who helps patients with different types of cancer and other health conditions. She specializes in treating colorectal cancer, pancreatic cancer, esophageal cancer, and many other diseases like familial adenomatous polyposis and magnesium deficiency.
Lara R. Lipton uses special skills and treatments to help her patients get better. She communicates with patients in a caring and understanding way, which makes them trust her. Patients feel comfortable talking to her about their health concerns.
To stay updated with the latest medical knowledge, Lara R. Lipton reads research papers and attends conferences. This helps her provide the best care for her patients. She also works closely with other medical professionals to share knowledge and improve patient outcomes.
Lara R. Lipton's work has had a positive impact on many patients' lives. She has helped people with cancer get better and live healthier lives. Her research on early onset pancreatic cancer has been published in a respected medical journal, showing her dedication to advancing medical knowledge.
One of the clinical trials she was involved in evaluated a new treatment for intrahepatic cholangiocarcinoma. This study aimed to improve the outcomes for patients with this type of cancer. By participating in such trials, Lara R. Lipton shows her commitment to finding better treatments for her patients.
Overall, Lara R. Lipton is a caring and knowledgeable medical professional who works hard to help her patients. Her dedication to research and collaboration with colleagues make her a trusted healthcare provider in her field.
Enrollment Status: Completed
Published: April 12, 2023
Intervention Type: Device, Drug
Study Drug: Cisplatin-Gemcitabine
Study Phase: Phase 2/Phase 3
